{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:35Z","timestamp":1791460835937,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rpth.2026.106968","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:18:47Z","timestamp":1789427927000},"page":"106968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0007-7943","authenticated-orcid":false,"given":"Parwana","family":"Hussaini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine-Lise","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Erik","family":"Astrup Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106968_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"N\u00c6Ss","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2026.106968_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2026.106968_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001155","article-title":"Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors","volume":"9","author":"Flinterman","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.rpth.2026.106968_bib5","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106968_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1538-7836.2007.02497.x","article-title":"Cancer and thrombosis: from molecular mechanisms to clinical presentations","volume":"5","author":"Buller","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib7","first-page":"1293","article-title":"Incidental pulmonary embolism in oncologic patients\u2014a systematic review and meta-analysis","volume":"29","author":"Meyer","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rpth.2026.106968_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01697-2019","article-title":"Clinical implications of incidental venous thromboembolism in cancer patients","volume":"55","author":"Mulder","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rpth.2026.106968_bib10","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jth.15461","article-title":"Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study","volume":"19","author":"Giustozzi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106968_bib12","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib13","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2020.08.042","article-title":"Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism","volume":"196","author":"Hannevik","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106968_bib15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients\u201430 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/a-2188-8773","article-title":"Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism","volume":"124","author":"Hussaini","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib19","first-page":"818","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry","volume":"100","author":"Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1520725","article-title":"Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism","volume":"15","author":"Svalastoga","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib22","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients","volume":"29","author":"Den Exter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib23","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/jth.15435","article-title":"Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"19","author":"Caiano","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106968_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2026.106968_bib27","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.2011.37.2730","article-title":"Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism","volume":"29","author":"O'Connell","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.critrevonc.2003.10.003","article-title":"The prothrombotic state in cancer: pathogenic mechanisms","volume":"50","author":"De Cicco","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.rpth.2026.106968_bib29","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/jth.13752","article-title":"The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort","volume":"15","author":"Gade","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106968_bib30","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1200\/JCO.2011.40.1810","article-title":"Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"30","author":"Ahlbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106968_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00282-2016","article-title":"Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study","volume":"49","author":"Font","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rpth.2026.106968_bib32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:37:52Z","timestamp":1791459472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926036265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2475037926036265"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106968","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106968"}}